This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Across transfusion-dependent anemias Unlock the Benefits of Total Body Iron Chelation With Once-daily Oral EXJADE
T2 improvements above the prevention threshold in mild-moderate cardiac iron overloaded patients with beta-thalassemia

TOOLS & RESOURCES

Learn more about Exjade

Learn more about EXJADE

Useful overview of relevant information for physicians new to EXJADE.

Learn more
Dosing Simulator

Dosing Simulator

Downloadable tool to help determine appropriate dosage and number of daily dispersible tablets according to individual patient weight, current therapy, and treatment goal.

Learn more
Safety Profile Across Anemia

Safety Profile Across Anemias

Several studies have demonstrated the safety of EXJADE.

Learn more
IPSS Calculator

IPSS calculator

Calculate estimated median survival for patients with MDS.

Learn more
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed

References

  1. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement and normalization of myocardial T2* in patients with β-thalassemia major treated with deferasirox (EXJADE®) for up to 3 years. Abstract presented at: 52nd Annual Meeting of the American Society of Hematology; December 2010; Orlando, Florida.
  2. Data on file. Novartis Pharma AG, Basel, Switzerland.
  3. Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010;34(9):1143-1150.
  4. Lee JW, Yoon SS, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010;116(14):2448-2454.